Journal
CLINICAL EPIGENETICS
Volume 8, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s13148-016-0182-9
Keywords
Castration-resistant prostate cancer; CBX2; Epigenetics; Metastatic prostate cancer; Polycomb
Categories
Funding
- Canadian Cancer Society Research Institute
- Canadian Institutes of Health Research
- Terry Fox Research Institute
- Prostate Cancer Canada
- BC Cancer Foundation
- Michael Smith Foundation for Health Research
Ask authors/readers for more resources
Background: While localized prostate cancer (PCa) can be effectively cured, metastatic disease inevitably progresses to a lethal state called castration-resistant prostate cancer (CRPC). Emerging evidence suggests that aberrant epigenetic repression by the polycomb group (PcG) complexes fuels PCa progression, providing novel therapeutic opportunities. Results: In the search for potential epigenetic drivers of CRPC, we analyzed the molecular profile of PcG members in patient-derived xenografts and clinical samples. Overall, our results identify the PcG protein and methyl-lysine reader CBX2 as a potential therapeutic target in advanced PCa. We report that CBX2 was recurrently up-regulated in metastatic CRPC and that elevated CBX2 expression was correlated with poor clinical outcome in PCa cohorts. Furthermore, CBX2 depletion abrogated cell viability and induced caspase 3-mediated apoptosis in metastatic PCa cell lines. Mechanistically explaining this phenotype, microarray analysis in CBX2-depleted cells revealed that CBX2 controls the expression of many key regulators of cell proliferation and metastasis. Conclusions: Taken together, this study provides the first evidence that CBX2 inhibition induces cancer cell death, positioning CBX2 as an attractive drug target in lethal CRPC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available